SR3335 is a selective agonist of the melanocortin-1 receptor (MC1R), primarily investigated for its anti-inflammatory properties in therapeutic applications within dermatology and ophthalmology. It has shown promise in treating skin conditions such as acne, rosacea, and psoriasis by targeting inflammatory pathways and modulating sebum production. In ophthalmology, it is being studied for mitigating dry eye disease through modulation of tear film stability and reduction of ocular surface inflammation, as well as for managing age-related macular degeneration (AMD) by protecting retinal cells from oxidative stress. Its anti-inflammatory and antioxidant effects position it as a candidate for various inflammatory and degenerative conditions, with research focusing on MC1R-mediated mechanisms rather than central melanocortin pathways like appetite regulation.